MELEMA and Lonza Enter into a Development Services Agreement to Further Progress MELEMA’s Cancer Therapeutic, ME-503 Hamburg, Germany and Basel, Switzerland, 21 July 2015 – Lonza and MELEMA Pharma GmbH announced today that they have entered into a service agreement for protein assessment services on MELEMA’s leading cancer therapeutic, ME-503. Under the agreement, Lonza will investigate the strong ME-503 induced DC stimulation and T cell responses. Analysis of T cell responses is a frequently used tool to monitor the activation of the immune system. About Lonza Lonza is one of the world’s leading and most-trusted suppliers to the pharmaceutical, biotech and specialty ingredients markets. We harness science and technology to create products that support safer and healthier living and that enhance the overall quality of life. Further information can be […]

Hamburg, August 19, 2014 – MELEMA Pharma GmbH, a biopharmaceutical company developing derivatives of natural compounds for the treatment of oncological and immunological diseases, today announced Phase II data demonstrating that its lead compound Aviscumine (ME-503), an immune potentiator, may improve survival of patients with refractory metastatic melanoma (stage IV). The data are published now in Journal for Immunotherapy of Cancer 2: 27 (2014). The open-label Phase II multicenter trial (NCT00658437)was designed to test the influence of subcutaneous injections of Aviscumine (ME-503) on progression-free survival (PFS) and overall survival (OS) of patients with unresectable metastatic melanoma (stage IV) after antineoplastic treatment failure. The trial included 31 eligible patients and was conducted at four German sites. The progression-free survival rate after […]